Treatment outcomes of patients with stage III non–small cell lung cancer and interstitial lung diseases receiving intensity‐modulated radiation therapy: A single‐center experience of 85 cases

Treatment outcomes of patients with stage III non–small cell lung cancer and interstitial lung diseases receiving intensity‐modulated radiation therapy: A single‐center experience of 85 cases

Abstract Objectives Whether curative‐intent radiotherapy could be safely applied to lung cancer patients with interstitial lung diseases (ILD) remains unclear. We aim to evaluate radiation induced lung toxicities (RILTs) and the efficacy of intensity‐modulated radiotherapy (IMRT) in these patients....

Full description

Bibliographic Details
Main Authors: Linfang Wu, Shijun Zhao, Hui Huang, Wenqing Wang, Tao Zhang, Zongmei Zhou, Qinfu Feng, Jun Liang, Zefen Xiao, Zhouguang Hui, Jima Lv, Nan Bi, Luhua Wang
Format: Article
Language:English
Published: Wiley 2022-06-01
Series:Thoracic Cancer
Subjects:
honeycombing
pulmonary fibrosis
pulmonary toxicities
radiotherapy
survival
Online Access:https://doi.org/10.1111/1759-7714.14418

Internet

https://doi.org/10.1111/1759-7714.14418

Similar Items